Journal Searches


Blood And Lymphatic Cancer: Targets And Therapy Indexing, Publication Fee / Time (2025)



Aim and Scope

The Blood And Lymphatic Cancer: Targets And Therapy is a research journal that publishes research in the field of lymphoma, anticancer agents, haematology, leukaemia. This journal is published by the Dove Medical Press. The ISSN of this journal is .

Also, please check the following important details about blood and lymphatic cancer: targets and therapy: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

The ISSN (International Standard Serial Number) is an 8-digit code used to uniquely identify journals. ISSN numbers are assigned by a network of ISSN National Centres, usually located at national libraries and coordinated by the ISSN International Centre based in Paris. The International Centre is an intergovernmental organization created in 1974 through an agreement between UNESCO and the French government.

Important Metrics

Journal Title: Blood and Lymphatic Cancer: Targets and Therapy
Publisher: Dove Medical Press
P-ISSN:
E-ISSN: 1179-9889
Language: English
Country of Publisher: United Kingdom
APC: Yes
Processing Time (Weeks): 16
Review Process: Anonymous peer review
Subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs

Indexing

The blood and lymphatic cancer: targets and therapy is indexed in:

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).


Publication fee

According to journal website, the publication fee of blood and lymphatic cancer: targets and therapy is around 3300 USD.

The blood and lymphatic cancer: targets and therapy has also Journal waiver policy (for developing countries, authors etc).

An article processing charge (APC), also known as a publication fee, is a fee which is sometimes charged to authors. Most commonly, it is involved in making a work available as open access (OA), in either a full OA journal or in a hybrid journal.


Journal Publication Time

The Journal Publication Time means the average number of weeks between article submission and publication. According to the journal website, the blood and lymphatic cancer: targets and therapy publishes research articles in 16 weeks on an average.



Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Blood And Lymphatic Cancer: Targets And Therapy?

If your research is related to lymphoma, anticancer agents, haematology, leukaemia, then visit the official website of blood and lymphatic cancer: targets and therapy and send your manuscript.

Tips for publishing in Blood And Lymphatic Cancer: Targets And Therapy:

  • Selection of research problem.
  • Presenting a solution.
  • Designing the paper.
  • Make your manuscript publication worthy.
  • Write an effective results section.
  • Mind your references.

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Final Summary

  • It is published by Dove Medical Press.
  • The journal is indexed in , DOAJ, PubMed, Embase.
  • It is an open access journal.
  • The publication time (Average number of weeks between article submission and publication) of the journal is 16 weeks.
  • The Publication fee (APC) of blood and lymphatic cancer: targets and therapy 3300 USD.

Sources: https://www.dovepress.com/blood-and-lymphatic-cancer-targets-and-therapy-journal







TOP RESEARCH JOURNALS

Credit and Source: Scopus, Clarivate, UGC CARE.